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Abstract 
Imaging genetics studies involving participants with major depressive disorder (MDD) have 
expanded. Nevertheless, findings have been inconsistent. Thus, we conducted a systematic 
review and meta-analysis of imaging genetics studies that enrolled MDD participants across 
major databases through June 30th, 2017. Sixty-five studies met eligibility criteria (N=4034 
MDD participants and 3293 controls), and there was substantial between-study variability in 
the methodological quality of included studies. However, few replicated findings emerged from 
this literature with only 22 studies providing data for meta-analyses (882 participants with 
MDD and 616 controls).  Total hippocampal volumes did not significantly vary in MDD 
participants or controls carrying either the BDNF Val66Met ‘Met’ (386 participants with MDD 
and 376 controls) or the 5-HTTLPR short ‘S’ (310 participants with MDD and 230 controls) 
risk alleles compared to non-carriers. Heterogeneity across studies was explored through meta-
regression and subgroup analyses. Gender distribution, the use of medications, segmentation 
methods used to measure the hippocampus, and age emerged as potential sources of 
heterogeneity across studies that assessed the association of 5-HTTLPR short ‘S’ alleles and 
hippocampal volumes. Our data also suggest that the methodological quality of included 
studies, publication year, and the inclusion of brain volume as a covariate contributed to the 
heterogeneity of studies that assessed the association of the BDNF Val66Met ‘Met’ risk allele 
and hippocampal volumes. In exploratory voxel-wise meta-analyses, MDD participants 
carrying the 5-HTTLPR short ‘S’ allele had white matter microstructural abnormalities 
predominantly in the corpus callosum, while carriers of the BDNF Val66Met ‘Met’ allele had 
larger grey matter volumes and hyperactivation of the right middle frontal gyrus compared to 
non-carriers. In conclusion, few replicated findings emerged from imaging genetics studies that 
included participants with MDD. Nevertheless, we explored and identified specific sources of 
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heterogeneity across studies, which could provide insights to enhance the reproducibility of this  
emerging field. 
 
Keywords: depression; genetic polymorphisms; diffusion tensor imaging; magnetic resonance 
imaging; voxel-based morphometry; meta-analysis 
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Abbreviations 
AD, axial diffusivity; MDD, Major depression disorder; MRI, magnetic resonance imaging; 
MD, mean diffusivity; SDM, Seed-based d Mapping; VBM, voxel-based morphometry; fMRI, 
functional MRI; HC, healthy controls; ES, effect size; DTI, diffusion-tensor imaging; FA, 
fractional anisotropy; FWHM, full width at half maximum; OFC, orbitofrontal cortex; UF, 
uncinated fasciculus; MFG, middle frontal gyrus; IFG, inferior frontal gyrus; BDNF, brain-
derived neurotrophic factor; COMT, catechol-o-methyl transferase; 5-HTTLPR, 5-HTT gene 
(SLC6A4) linked polymorphic region; DLPFC, dorsolateral prefrontal cortex; VLPFC, 
ventrolateral prefrontal cortex; SLF, superior longitudinal fasciculus; ILF, inferior longitudinal 
fasciculus; ROI, region of interest; HC, healthy controls; WBA, whole brain analysis; RCs, 
carriers of risk genotypes; NRCs, non-carriers of risk genotypes; DMN, default mode network; 
TBSS, tract-based spatial statistics. 
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1. Introduction 
Major depressive disorder (MDD) is a chronic condition with an estimated lifetime prevalence 
of 14.6% in high- income countries and 11.1% in low and middle- income countries. The 
disorder is a leading source of disability worldwide (Bromet et al., 2011; Zhang et al., 2016). 
The pathophysiology of depression remains incompletely understood and may involve the 
complex interaction of genetic and environmental factors  (Otte et al., 2016; Vialou et al., 
2013). The heritability of depression has been estimated to be 37% according to twin studies 
(Sullivan et al., 2000). However, the search for genetic risk variants for depression has been 
challenging, partially due to the phenotypic heterogeneity of this syndrome that may imply 
distinct genetic architectures (Kendler, 2016; Mullins and Lewis, 2017). Only with the recent 
development of genome-wide approaches and the inclusion of large samples sizes, the field has 
witnessed the identification of the first genetic variants  of risk for depression that reached 
genome-wide significance (CONVERGE consortium, 2015; Direk et al., 2017; Hyde et al., 
2016; Mullins and Lewis, 2017).   
 Imaging genetics is a field of investigation that aims to gain mechanistic insights on the 
impact of genetic variations on brain structure, chemistry, and function in health and disease 
(Carter et al., 2017; Pereira et al., 2017). Several approaches can be used in imaging genetics 
studies. In the candidate gene approach, a hypothesis-driven association with a genetic 
variation is related to neuroimaging measures. This approach also includes genetic variants 
derived from a genome-wide association study (GWAS), where the identified variants can be 
further investigated for possible influences in brain structure or function, theoretically 
enhancing the degree of specificity and confidence of the hypothesis. A second approach is the 
discovery-based approach (Carter et al., 2017). This adopts a non-theoretical approach and do 
not specify a variant based on prior observation (Carter et al., 2017). This include GWAS 
without the further selection of candidates or studies where a neuroimaging abnormality per se 
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could be assessed as a phenotype for the investigation of the impact of genetic variations on 
specific structural or functional neuroimaging abnormalities. This later approach may also be 
used in a hypothesis-free basis to investigate genetic variations that could survive stringent 
statistical correction for multiple comparisons on specific imaging (endo) phenotypes. Finally, 
as a disorder or trait may be associated with several genes, there is the more recent polygenic 
approach, in which several variants can be analyzed in the form of a polygenic risk score, or 
the occurrence of summation or epistatic interactions between different genes can be 
investigated (Wray et al., 2014). 
 Although imaging genetics studies have flourished in the literature, concerns regarding 
their reproducibility have been raised (Carter et al., 2017). For example, a recent systematic 
review of 40 imaging genomics studies probing the impact of 7 genes that reached genome-
wide significance for schizophrenia and bipolar disorder found that most studies  were limited 
by small sample sizes, poor clinical-genetic design, and a lack of statistical correction for 
multiple comparisons, while few true replications were reported (Gurung and Prata, 2015). 
Similarly, a recent systematic review that included 44 imaging genetics studies enrolling 
participants with bipolar disorder found a single replicated finding, namely the association of 
the BDNF Val66Met ‘Met’ allele with reduced hippocampal volumes (Pereira et al., 2017). 
 Several imaging genetics studies involving participants with unipolar depression have 
been performed (Alexopoulos et al., 2009; Frodl et al., 2008; Frodl et al., 2004; Frodl et al., 
2010; Hickie et al., 2007; Kanellopoulos et al., 2011; Taylor et al., 2005; Wang et al., 2012). 
However, to our knowledge, findings have been inconsistent across studies, with most studies 
adopting the candidate gene approach. For example, one study found that individuals with 
MDD who were carriers of the BDNF Val66Met ‘Met’ risk allele had smaller hippocampi than 
non-carriers (Frodl et al., 2014), while another study failed to replicate this finding (Cole et al., 
2011). Similarly, the effects of polymorphisms of the serotonin transporter promoter region (5-
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HTTLPR) on hippocampal volumes in individuals with MDD have not been consistent across 
studies. While some studies suggest that carriers of the 5-HTTLPR long ‘L’ allele could exhibit 
smaller volumes (Taylor et al., 2005), others found no effect of the polymorphism on 
hippocampal volumes (Ahdidan et al., 2013). Several potential sources of heterogeneity could 
explain the discrepant findings, including the selection of samples with different characteristics 
across studies, or different procedures used for image acquisition and analysis. For instance, the 
correlations between different automated methods for the assessment of amygdala and 
hippocampal volumes against manual segmentation methods do not appear to correlate strongly 
(Schoemaker et al., 2016). 
 The emergence of many imaging genetics studies conducted in participants with MDD 
in the literature as well as the discrepant findings across studies prompted us to perform a 
comprehensive systematic review and meta-analysis of imaging genetics studies involving 
participants with MDD. The identification of replicated evidence from studies that reported the 
impact of gene variants on both pre-determined regions of interest (ROI) as well as functional 
and structural magnetic resonance imaging (MRI) studies that provided whole-brain analysis 
were synthesized. In addition, when replicated evidence was available we estimated the power 
of the meta-analysis due to concerns of lack of proper statistical power in this specific field 
(Carter et al., 2017). We considered for inclusion studies that primarily enrolled participants 
with MDD to identify possible imaging endophenotypes that could have emerged from this 
literature. However, neuroimaging data that assessed the effects of the same genetic variants in 
control groups were also extracted whenever available. This approach aimed to identify 
possible gene versus group (i.e., MDD compared to controls) interactions on brain structure and 
function. If a particular genetic variant is associated with an imaging finding in MDD subjects, 
we expected that carriers of the polymorphism would have altered values with respect to the 
non-carriers, which would not occur in the healthy controls carriers of that particular allele. 
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Whenever a genetic variant is associated with imaging alterations in either MDD or HCs, it is 
expected that the effect sizes of the differences with respect to the non-carriers of the allele are 
larger for the MDD subjects. Furthermore, sources of heterogeneity across studies were 
explored aiming to shed light on possible factors that could be harmonized in future 
collaborative efforts to improve the overall reproducibility of this field.  
2. Methods 
2.1. Search strategy and eligibility criteria 
This systematic review and meta-analysis complied with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher et al., 2010), and 
followed an a priori defined protocol (available upon request to the authors). The EMBASE, 
PubMed/MEDLINE and PsycINFO electronic databases were searched from inception up to 
June 30th, 2017 (detailed search strings are provided in the Supplementary Material, available 
online). The search strategy was augmented through hand searching the reference lists of 
eligible articles. Two investigators (LPP and BPF) independently screened the tiles/abstracts of 
retrieved references, assessed full-text for eligibility, extracted data and rated the 
methodological quality of eligible studies. Disagreement were resolved either through 
consensus or consultation with a third investigator (CAK or AFC). The following inclusion 
criteria were applied: (1) human studies that enrolled participants of any age meeting diagnostic 
criteria for depression (for example, DSM or ICD) regardless of the inclusion of a healthy 
control group or design (e.g. cross-sectional, case-control or prospective studies were eligible); 
(2) provided an association of genetic variants and structural or functional MRI measures; and 
(3) studies that provided either ROI analysis (e.g., mean values of volumes or functional 
activation, standard deviations and/or statistical difference [p] or [t] between groups) or whole 
brain results of changes in a stereotactic space in three dimensional coordinates (x, y, z), using 
significance thresholds either corrected for voxel based multiple comparisons or uncorrected 
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with spatial extent thresholds.  The following exclusion criteria were considered: (1) extractable 
data were not available; (2) a larger study reporting on the same association and with an 
overlap of samples was available; (3) investigations that used imaging methods other than 
structural or functional MRI; (4) studies that enrolled samples with mixed diagnoses unless 
data for MDD was reported separately; (5) studies that reported solely associations with 
treatment response or other clinical measures; (6) preclinical or post-mortem studies, case 
series, literature reviews, conference papers, meeting abstracts or meta-analyses. We included 
studies regardless of the specific ROI (i.e., brain area) investigated, and there was also no 
restriction relative to the inclusion of studies that assessed specific gene variants.  The overall 
agreement between the two investigators was adequate (84.9%). 
2.2. Data Extraction 
Corresponding authors were contacted in at least two occasions when extractable data were not 
provided in the original report. The following variables were considered for extraction: first 
author, year of publication, sample size, age of participants, % of females, diagnostic criteria 
for MDD, number of previous major depressive episodes, depression severity scores, use of 
psychotropic medications (percentage of the sample that used antidepressants and/or 
antipsychotics), name of the gene(s) and allele groups assessed, MRI scanner field strength (1.5 
T vs. 3.0 T), and details of imaging methods and procedures. For ROI analyses, mean volume 
or activation within the ROI and the standard deviation (SD) or t and P values with the 
direction of the change were extracted, as well as ROI tracing methods (i.e., manual vs. 
automatic). For voxel-wise studies (voxel-based morphometry [VBM] or whole-brain 
functional MRI analysis [fMRI]), coordinates were extracted according to the ES-SDM method 
(Radua et al., 2012). Data from control groups were also extracted whenever a study included a 
comparison group. The agreement between the two investigators was 91.2%. 
2.3. Methodological quality appraisal 
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A previously published 11- item tool (Karg et al., 2011) was used to rate the methodological 
quality of included studies. The items and quality ratings are provided in Table S8 (available 
online). This tool is based on criteria of the Strengthening the Reporting of Genetic Association 
Studies (STREGA) (Little et al., 2009) and the Strengthening Reporting of Observational 
Studies in Epidemiology (STROBE) (von Elm et al., 2008). It was previously used in a meta-
analysis of imaging genetics studies (Molendijk et al., 2012a). An overall quality score was 
computed as the percentage of criteria met by each study. Agreement among the independent 
raters was adequate (82.3 %). 
2.4. Statistical analysis  
2.4.1. Meta-analyses of studies that provided ROI data 
A standardized mean difference [Hedges’s g; Hedges (1981)] was estimated for each ROI 
measure (volume or activation) (Lau et al., 1997).  positive value of this metric indicated 
decreased ROI volumes or functional activity in carriers in comparison to non-carriers of the 
genetic risk variant, in either participants with MDD or healthy controls (HCs).  
Effect size (ES) estimates were pooled using a random-effects model (DerSimonian and 
Laird, 1986) when at least three individual studies investigated the association. For meta-
analyses of total volume or activation, we first estimated study- level ESs for the studies that 
provided separate measures for the left and right sides. The unilateral ESs were combined to 
obtain a single ES for the study. These were then pooled together with studies that provided 
only bilateral measures to obtain the final meta-analytic estimate. Heterogeneity across studies 
was quantified with the I2 statistic and assessed using the Cochran’s Q test (Borenstein et al., 
2009; Patsopoulos et al., 2009). 
Publication bias was assessed by inspection of funnel plot asymmetry and through the 
Egger’s test (Egger et al., 1997). Small-study effects (indicative of publication bias) were 
defined by a P-value < 0.1 in the Egger’s test combined with the ES of the largest study more 
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conservative or in the opposite direction in comparison to the overall ES estimate (Carvalho et 
al., 2016a; Carvalho et al., 2016b). The trim-and-fill procedure was used to adjust the ES for 
publication bias when small-study effects were verified (Duval and Tweedie, 2000), while the 
fail-safe N (i.e., the file drawer statistic) was used to determine how many additional studies 
would be necessary to turn a significant ES non-significant (Rosenthal, 2017). 
 We explored potential sources of heterogeneity using either subgroup or random-effects 
meta-regression analyses (Trikalinos et al., 2010). Meta-regression analyses considered the 
following potential moderators: sample size, mean age, % of females, methodological quality 
scores, year of publication, mean depressive symptom scores, mean illness duration in years, 
and % of participants using psychotropic medications. All analyses were conducted in Stata MP 
software version 14.0 (Stata Corp, College Station, TX, USA) using the metan package. We 
estimated the power of each summary ES estimate across a hypothetical range of ‘true’ ESs 
with a method developed by Hedges and Pigott (2001). Statistical significance was considered 
at an alpha level of 0.05. 
2.4.2. Meta-analyses of studies that provided whole-brain data 
The effect-size version of signed differential mapping (ES-SDM) was used to perform separate 
voxel-based meta-analyses of regional gray matter volume, diffusion-tensor imaging fractional 
anisotropy measures or functional brain response abnormalities. ES-SDM is a relatively novel 
method that incorporates aspects of the activation likelihood estimate (ALE) and multilevel 
kernel density analysis (MKDA) approaches (Radua and Mataix-Cols, 2009, 2012; Radua et 
al., 2012). For each study, peak coordinates were used to recreate a map of the ES of the 
differences between carriers vs. non-carriers of genetic risk variants, and then a standard 
random-effects variance-weighted meta-analysis was performed for each voxel. Default ES-
SDM kernel size and thresholds were used (FWHM = 20 mm, voxel P = 0.005, peak height Z = 
1, cluster extent = 10 voxels) (Radua et al., 2012). Meta-analyses were conducted when whole-
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brain measures were available for at least two individual datasets for each method. The CARET 
v5.65 Software was used to visualize SDM results (http://brainmap.wustl.edu/caret.html). 
3. Results 
3.1. Study selection  
The literature search retrieved 2409 records, while an additional reference was found after 
reviewing the reference lists of included articles. After removal of duplicates, 1499 unique 
references were screened. One thousand, three hundred and eighty-eight references were 
excluded after title/abstract screening. Of the 111 full- texts assessed, 46 were excluded with 
reasons (see Table S1, supplementary online material). Therefore, 65 imaging genetics studies 
that assessed 31 candidate genes met inclusion criteria for the qualitative systematic review 
(Figure 1), which provided data from 7327 participants (4034 participants with MDD and 3293 
HCs). Finally, 22 studies provided data for quantitative meta-analyses (N=1498; 882 
participants with MDD and 616 HCs). See supplementary online results for details of included 
references. 
[Please insert Figure 1 here] 
3.2. Characteristics and methodological quality assessment of included studies  
Thirty-one of the 65 studies investigated non-replicated associations of candidate gene 
polymorphisms and imaging findings (Table S2, available online). The remaining 34 studies 
(22 included in the meta-analyses) reported replicated associations for the 5-HTTLPR (k=16), 
BDNF Val66Met (k=13) and the COMT Val158Met (k=5) polymorphisms (see Tables S3 to 
S7, available online). 
 Forty-six studies (70.1%) included a HC comparison group, while the remaining 
enrolled only participants with MDD. Overall, 1664 participants with MDD (range = 1 to 144) 
carried genetic variants of risk (RCs), while 1460 (range = 5 to 169) were non-risk carries 
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(NRCs). For HCs, 921 (range = 2 to 123) were RCs, whilst 1668 (range = 4 to 508) were 
NRCs. 
 Across included studies, most participants were females (65.1% in MDD and 57.5% in 
HC groups, respectively), and the mean age was 45.7 (SD = 11.8) in subjects with MDD and 
43.2 (SD = 13.4) among HCs. Medication status was reported in 44 studies (67.7%), of which 
12 (27.3%) reported that at least 50% of participants with MDD were currently taking more 
than one psychotropic medication. Eleven studies (16.9%) reported that MDD samples were 
drug-free at the time of MRI scan. There was substantial between-study variability in the 
methodological quality, but it was overall good (median = 89%, range 63–100; Table S8, 
available online). 
 Twenty-four studies (36.9%) assessed brain volume using ROIs, of which 15 (62.5%) 
used manual techniques to segment the tissue volume. The remaining used either semi-
automated or automated segmentation methods (4.2% and 33.3%, respectively). Across these 
studies, the hippocampus was the most extensively investigated brain structure (79.2%), 
followed by the amygdala (12.5%), and the caudate (8.3%). The putamen, orbitofrontal cortex 
(OFC), dorsolateral prefrontal cortex and striatum were reported only by single studies. Finally, 
seven studies (10.7%) used voxel-based-morphometry to assess volume. 
 Twenty-four studies (36.9%) used functional blood-oxygen level dependent (BOLD) 
fMRI during tasks. Of these studies, 15 (62.5%) used a ROI for analysis (amygdala [k=10], 
caudate [k=2], insula [k=1], prefrontal regions [k=3], anterior cingulate cortex [k=3] and 
parahippocampal region [k=1]), whereas 9 (37.5%) used whole-brain analysis. The sad faces 
paradigm (k=6), negative pictures (International Affective Picture System - IAPS) (k=3), 
fearful faces (k=1), emotional processing (k=1), emotional memory (k=1), episodic memory 
(k=1) and emotional word processing (k=2) were the most frequently used tasks across 
functional studies. Three studies provided whole-brain resting state fMRI data. 
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 Finally, 9 studies (13.8%) used diffusion-tensor imaging (DTI) to assess brain 
connectivity. Most of these studies performed whole-brain tractography (volume-based [k=2] 
and tract-based spatial statistics analyses [k=5]), while 4 studies reported diffusion metrics for 
ROIs. 
 The MRI scanner field strength ranged from 1.5T to 3.0T, with the majority using 3.0T 
(56.9%) scanners. Six studies did not inform the MRI field strength. 
3.3. Meta-analyses of studies that provided ROI data 
Of the 22 studies included in the meta-analyses, 16 (72.7%) reported ROI metrics 
(hippocampal volume [k=13] and amygdala function [k=3]). Three studies reported data on 
both 5-HTTLPR and BDNF Val66Met polymorphisms (Cole et al, 2011; Jaworska et al, 2016; 
Phillips et al, 2015). Furthermore, 3 studies (Benjamin et al, 2010; Opmeer et al, 2013; Wang et 
al, 2012) did not provide sufficient information to estimate effect sizes because data for both 
RCs and NRCs groups were presented for the combined MDD and HC groups (Table S5, 
online supplement).  
[Please insert Table 1 here] 
3.3.1. 5-HTTLPR polymorphism 
Hippocampal volume differences associated with the 5-HTTLPR polymorphism were 
investigated in 8 studies. Among participants with MDD, 211 were carriers of the 5-HTTLPR 
short ‘S’ risk allele (RCs), and 99 were carriers of the long ‘L’ non-risk allele (NRCs). Five of 
the eight studies also provided data for HCs (160 RCs and 70 NRCs). Hippocampal volumes of 
the participants with MDD or HCs who were carriers of the short ‘S’ risk allele were not 
different than carriers of the long ‘L’ allele (MDD, g = 0.193; P = 0.157; HC, g = 0.200; P = 
0.163; Table 1 and Fig. 2a; Figure S1, available online). No evidence of small-study effects 
was observed in the meta-analysis of MDD participants, while there was evidence of this type 
of bias in the meta-analyses of the HC comparison group for the total or right hippocampal 
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volumes (Table 1). This effect sizes did not survive correction for publication bias (Total: g = 
0.127, 95%CI = -0.133‒0.387; right: g = 0.080, 95%CI = -0.180‒0.340). No statistically 
significant differences emerged for the right or left hippocampal volumes for either MDD or 
HC subjects (Table 1; Figures S2‒S5, available online). 
 Heterogeneity was low in the meta-analyses of hippocampal volumes in MDD subjects 
(I2 = 15.5%‒30.0%) and inexistent for HCs (Table 1). Meta-regression showed that differences 
in gender distribution (% females) in the MDD group emerged as a significant moderator, as a 
higher % of females was associated with a reduced difference in total hippocampal volume 
between carriers of the 5-HTTLPR short ‘S’ allele and non-carriers (Table S9). Subgroup 
analyses further showed that heterogeneity was higher in studies that employed manual tracing 
compared to those that used semi-automated or automated segmentation methods (I2 = 37.1%). 
In studies that enrolled a younger or predominantly female MDD sample, total hippocampal 
volume in carriers of the 5-HTTLPR ‘S’ allele was reduced when compared to non-carriers (% 
of females in sample >= 70%, g = 0.635, P = 0.006; age < 40 years old, g = 0.635, P = 0.016; 
Table S11). Finally, for MDD subjects that were drug-free during assessment, carriers of the 
‘S’ allele had reduced right hippocampal volume in comparison to carriers of the ‘L’ allele (g = 
0.520, P = 0.045; Table S11, available online).  
 Total amygdala activation was investigated in 3 studies (Table 1). In these studies, the 
neurofunctional responses to sad faces relative to neutral faces was considered as activation. 
There was no difference in amygdala activation between carriers of the 5-HTTLPR ‘S’ allele 
(RCs) and carriers of the 5-HTTLPR ‘L’ allele (NRCs) in both MDD (g = -0.896; P = 0.145) 
and HC subjects (g = -0.364; P = 0.613; Table 1; Figures S6 and S7, available online). 
Heterogeneity was very large (I2 = 84.8% for MDD and 86.5% for HC). 
[Please insert Figure 2 here] 
3.3.2. BDNF Val66Met polymorphism 
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Eight studies investigated hippocampal volume differences between carriers of the BDNF 
Val66Met ‘Met’ risk allele (RCs) and carriers of the BDNF Val66Met non-risk allele (‘Val’; 
NRCs). The BDNF Val66Met ‘Met’ allele was not significantly associated with alterations in 
total hippocampal volume in MDD subjects (g = 0.029; P = 0.832) or HCs (g = 0.221, P = 
0.662 Table 1 and Fig. 2b). Moreover, right or left hippocampal volumes in both MDD and HC 
groups were also similar in carriers of the ‘Met’ allele in comparison to non-carriers (MDD 
group: right g = 0.034, P = 0.837; left g = 0.027; P = 0.825; HC group: right g = 0.264, P = 
0.331; left g = 0.177, P = 0.291; Table 1 and Figs. S9‒S12, available online). No evidence of 
small-study effects was observed and between-study heterogeneity was large (Table 1), 
especially for studies that measured the right hippocampus (MDD subjects: I2 right = 54.6%; I2 
left = 17.2%; HCs: I2 right: 82.6%, I2 left: 55.6%).  
 The methodological quality of included studies emerged as a significant moderator in 
meta-regression analysis of studies that measured the right hippocampus in the MDD group 
(Table S9), while publication year was a significant moderator in studies that measured the left 
hippocampus in the HC group (Table S10). The ES estimate was higher (i.e. indicating smaller 
hippocampal volumes as a function of the ‘Met’ allele carrier status) in studies with better 
methodological quality and lower with increasing publication year, respectively. In addition, 
subgroup analyses suggested that heterogeneity was absent in studies in MDD subjects that 
included total brain volume as a covariate (Table S11). 
3.4. Meta-analyses of studies that provided whole-brain data 
From the 22 studies included in the meta-analyses, 6 reported whole-brain data and were 
included in the SDM meta-analyses. Two studies used VBM to assess grey matter volume, 2 
used DTI to assess brain white-matter differences, and the remaining two used fMRI to 
investigate brain activation. These studies investigated the 5-HTTLPR or the BDNF Val66Met 
polymorphism in MDD subjects. 
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3.4.1. 5-HTTLPR polymorphism 
The role of the 5-HTTLPR polymorphism in MDD was investigated with whole-brain MRI 
techniques in 5 studies (k=2 DTI; k=2 fMRI; k=1 VBM; Tables S6 and S7, available online). 
None of the two voxel-wise functional studies reported statistically significant results (Table 
S6). The VBM study found a statistically significant reduction in total hippocampal volumes 
(Frodl et al, 2008). Nevertheless, a small volume correction was applied to this ROI, which 
prevented its inclusion in a multimodal cortical meta-analysis. Therefore, a SDM meta-analysis 
was performed including the 2 DTI studies. Various brain regions with statistically significant 
decreases in white-matter FA in MDD participants carrying the 5-HTTLPR short ‘S’ allele 
compared to non-carriers were verified, with a predominance of voxels centered in the corpus 
callosum (Fig. 3; Table S14, available online).  
[Please insert Figure 3 here] 
3.4.2.BDNF Val66Met polymorphism 
Four studies met criteria for SDM meta-analysis (k=2 fMRI, k=2 VBM; Table S6, available 
online) and were pooled using a multimodal cortical analysis. Participants with MDD carrying 
the BDNF Val66Met ‘Met’ risk allele presented conjoint abnormalities with an increase in gray 
matter volumes accompanied by an hyperactivation or failure of deactivation in the right 
middle frontal gyrus (orbitofrontal region; Fig. 4; Table S15, available online). One fMRI study 
used an activation task [emotional appraisal of scenes from the IAPS; Lisiecka et al. (2015)], 
whereas the other included fMRI study used a resting-state approach (Yin et al., 2015).  
[Please insert Figure 4 here] 
4. Discussion 
To our knowledge, this systematic review and meta-analysis provides the most extensive 
synthesis to date of studies that investigated the association of putative risk genetic variants 
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with structural and functional neuroimaging findings in individuals with MDD. All included 
studies followed a candidate gene approach, while no studies that followed a discovery-based 
approach (Carter et al., 2017) and that provided extractable data for MDD participants were 
identified. Although 65 studies were identified, only a few replications could be meta-analyzed. 
These studies investigated associations related to the 5-HTTLPR and BDNF Val66Met risk 
polymorphisms. Moreover, our analyses identified possible sources of heterogeneity across 
studies, which might provide insights for the design of future studies that could enhance the 
overall reproducibility in the field of imaging genetics in MDD. 
 We found no evidence for an association of either the 5-HTTLPR short ‘S’ allele or the 
BDNF Val66Met ‘Met’ risk polymorphisms and hippocampal volumes in either participants 
with MDD or HCs in studies that provided ROI data (see Table 1 and Fig. 2). Also, this finding 
was confirmed in an exploratory multimodal whole-brain meta-analysis of studies assessing the 
impact of the BDNF Val66Met ‘Met’ allele on brain structure and function (see Fig. 4) while 
no replicated evidence for whole-brain structural MRI abnormalities associated with the 5-
HTTLPR risk polymorphism was available. A functional variation in the promoter serotonin 
transporter gene (also referred to as SLC6A4), and in particular the low-expressing short (‘S’) 
allele has been implicated in the development of depression following stress exposure (Caspi et 
al., 2010; Caspi et al., 2003). Nevertheless, a recent collaborative individual-participant meta-
analysis provided no evidence for such a gene-environment interaction of the 5-HTTLPR 
polymorphism and depression (Culverhouse et al., 2017). Our finding suggests that, if this 
polymorphism confers a risk for MDD, then its effect could be mediated by a mechanism other 
than an influence on hippocampal volumes. However, it is worthy to note that meta-regression 
and subgroup analysis identified several possible sources of heterogeneity that could have 
influenced these ES estimates. For example, characteristics of samples across studies (i.e., 
gender) and medication status appeared to moderate these results (see Tables S9 to S12). 
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Furthermore, heterogeneity was lower in studies that used automated segmentation methods 
instead of manual or semi-automated ones (see Tables S11 and S12). This finding is consistent 
with a previous report that verified that even among skillful raters the measurement of 
hippocampi through manual segmentation methods could be prone to bias (Maltbie et al., 
2012).    
 Several lines of evidence point to a role for BDNF in the pathophysiology of 
depression. BDNF is the pivotal mediator of the neurotrophin hypothesis of depression, which 
postulates that MDD is secondary to abnormalities in brain plasticity within brain regions that 
regulate emotion and memory, including the hippocampus (Duman et al., 1997). Furthermore, 
preclinical evidence suggests that the therapeutic effects of antidepressants result from the up-
regulation of hippocampal BDNF expression (Duman and Monteggia, 2006). Moreover, 
clinical studies indicate that peripheral levels of BDNF are lower in participants with MDD 
compared to HCs, and may be influenced by antidepressant treatment (Molendijk et al., 2014). 
The BDNF Val66Met SNP, which represents the substitution of a valine (Val) by a methionine 
(Met) at codon 66, modifies the sorting of the BDNF protein and its availability in the synaptic 
cleft. Interestingly Met/Met transgenic mice exhibit a decrease in activity-dependent secretion 
of BDNF, smaller hippocampal volumes and lower dendritic complexity of hippocampal 
neurons (Chen et al., 2006; Chen et al., 2004). Our findings are consistent with a previous 
meta-analysis that also found no evidence of an association of the Val66Met SNP and 
hippocampal volumes across neuropsychiatric disorders (Harrisberger et al., 2015). 
Furthermore, MDD is frequently accompanied by cognitive dysfunction encompassing several 
domains (including declarative memory) that may persist even during symptom remission 
(Bortolato et al., 2014; Bortolato et al., 2016). Our data also concur with two previous reports 
that found no significant association of the BDNF Val66Met SNP and emotionally neutral 
declarative memory retrieval in individuals with MDD (Benjamin et al., 2010; Molendijk et al., 
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2012b). Nevertheless, it should be pointed out that there was substantial variability in the 
methodological quality of included studies, which emerged as a possible source of 
heterogeneity across studies in meta-regression analyses (see Table S9). 
 The meta-analysis of whole-brain DTI studies showed that the 5-HTTLPR 
polymorphism was associated with widespread microstructural WM abnormalities. There was 
evidence of decreased FA values, with a predominance in voxels centered in the corpus 
callosum (CC; see Figure 3). This finding is in accordance with recent meta-analyses of DTI 
studies. Wise et al. (2016a) showed that MDD is associated with a significant decrease in FA 
values in the genu of the CC. A separate meta-analysis, conducted in first-episode, medication-
naïve participants with MDD, also showed decreased FA in the CC as well as other regions 
(Chen et al., 2017). Furthermore, lower FA values in the CC was previously reported in 
adolescents at high family risk for depression compared to controls without a family history of 
mental disorders (Huang et al., 2011). The corpus callosum is the largest myelinated WM tract 
in the human brain. It interconnects the cerebral hemispheres to integrate motor, perceptual, 
and high- level ‘hot’ and ‘cold’ (e.g., executive function) cognitive functions. There is evidence 
that subsets of individuals with MDD have impairment in these cognitive functions (Bortolato 
et al., 2014; Hofer and Frahm, 2006; Miskowiak and Carvalho, 2014), and we can speculate 
that the impaired connectivity of the CC may play a role in MDD pathophysiology. Indeed, 
postmortem and preclinical studies suggest that aberrations in myelination may be involved in 
the etiology of depression (Tham et al., 2011), while effects of standard antidepressants may at 
least partly involve pathways governing myelination (Bartzokis, 2012). The current findings 
suggest that the 5-HTTLPR polymorphism may underpin these connectivity abnormalities in 
MDD subjects. However, as only two independent studies were included in our meta-analysis, 
further well-designed studies are warranted to confirm these preliminary findings. 
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 Previous evidence suggests that the 5-HTTLPR polymorphism could confer a lower 
resilience to stress via the modulation of amygdala activation to emotional faces [see Caspi et 
al. (2010) for a review]. Our meta-analysis provided no evidence of abnormal amygdala 
reactivity to sad faces compared to neutral faces in participants with MDD who carried the 5-
HTTLPR ‘S’ polymorphism compared to carriers of the 5-HTTLPR ‘L’ polymorphism (see 
Table 1). However, this finding must be interpreted with caution, as the heterogeneity was 
large, and only three independent datasets were available. Notwithstanding evidence from 
postmortem brain studies as well as PET/SPECT studies suggest the expression of the serotonin 
transporter (5-HTT) is lower in the amygdala of MDD subjects compared to controls, the 
findings have not been consistent across studies, and heterogeneity is large (Gryglewski et al., 
2014; Spies et al., 2015). Therefore, evidence from diverse approaches (ranging from 
postmortem to imaging genetics studies) are still necessary to clarify the effects of the 5-
HTTLPR polymorphism and the 5-HTT in the amygdala in the pathophysiology of depression. 
 Multi-modal SDM meta-analysis of 2 VBM studies and 2 fMRI studies observed that, 
relative to carriers of the non-risk ‘Val’ allele, MDD participants carrying the BDNF Val66Met 
‘Met’ allele were characterized by conjoint increased activation or failure to deactivate as well 
as increased GM volumes in a cluster encompassing the right MFG (BA 44; see Fig. 4). A 
recent multi-modal meta-analysis of VBM studies found a significant reduction in the right 
MFG in individuals with MDD relative to HCs (Wise et al., 2016b). This finding has also been 
replicated in a meta-analysis that included only studies involving first-episode MDD 
participants (Zhang et al., 2016). However, our counterintuitive finding should be regarded as 
exploratory as only two VBM studies were included, and thus we could not verify the 
robustness of our findings (for example, through jack-knife sensitivity analysis in which one 
study is removed per iteration). Furthermore, one of the VBM studies, which reported higher 
right MFG volumes, enrolled only participants with melancholic depression (Cardoner et al., 
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2013). Therefore, this finding may not be extrapolated to the broad depression phenotype. 
However, it is noteworthy that hyperactivation or failure to deactivate the right MFG has been 
implicated in the neurobiology of depression. For example, a recent study provided evidence 
that this functional abnormality could be related to autobiographical problem-solved deficits 
associated with rumination in depression (Jones et al., 2017). Along similar lines, the right 
MFG is part of the default mode network (DMN), and failure to deactivate the DMN has been 
implicated in cognitive control deficits in depression (Jacobs et al., 2014; Pizzagalli, 2011; 
Rodriguez-Cano et al., 2017). But as only two fMRI studies were included, which employed 
either resting-state conditions or used an emotional cognitive task, these findings are also 
limited and should be taken as preliminary.  
4.1. Strengths and limitations 
The main strength of our work is the inclusion of a large body of data, and the use of state-of-
the-art statistical methods. These provide a quantitative appraisal of the available evidence and 
also allow the identification of potential sources of heterogeneity across studies.  
 However, some limitations deserve mention. First, few replicated findings were identified. 
Second, our power analysis suggests that most meta-analytic estimates reported herein are 
underpowered. Therefore, findings should be interpreted with caution, with the exception of the 
ES estimates on the association of the 5-HTTLPR ‘S’ allele with total hippocampus volume in 
participants with MDD or HCs, and the association of the BDNF Val66Met ‘Met’ allele with 
left hippocampal volume in participants with MDD, which were adequately powered (see Table 
S13).  
 This review also identified potential sources of heterogeneity across studies that could 
have influenced the findings. However, depression is a multifaceted and heterogeneous 
phenotype, and thus the observed heterogeneity could reflect ‘true’ heterogeneity. Moreover, 
other possible sources of heterogeneity could not be explored due to lack of available data. An 
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example is the frequent association of MDD with obesity and metabolic abnormalities (de Melo 
et al., 2017; Liu et al., 2014). It has been proposed that these co-occurring conditions could 
impact neuroimaging findings in depression (Cha et al., 2014; Gupta et al., 2015).  
 The literature on either structural or functional neuroimaging data is limited by an excess 
of reporting biases (Fusar-Poli et al., 2014; Ioannidis, 2011). Indeed, a recent large-scale 
whole-brain meta-analysis of functional neuroimaging studies suggested a lack of consistency 
and reproducibility across studies conducted in MDD samples (Muller et al., 2017). Our 
findings could be affected by those biases as well. Additionally, the studies included in our 
review used a candidate gene approach. As the potential methodological strengths of 
exploratory genome-wide approaches are being increasingly recognized (Carter et al., 2017), an 
unbiased assessment is less likely with the methodology employed in the studies identified by 
our review. Furthermore, although a validated tool for the appraisal of the methodological 
quality of gene- imaging studies is currently unavailable, we found substantial between-study 
variation in the methodological quality of included studies (see Table S8), which was also a 
source of heterogeneity (see Table S9). Therefore, these variations in study methodology limit 
the interpretation of the findings. 
 Finally, it is worthy to note very few studies have separated carriers of two risk alleles 
(i.e., homozygotes) from participants carrying a single allele of risk. Therefore, a putative dose-
response effect of risk alleles cannot be clearly established.   
4.2. Research implications 
We observed that both sample characteristics across studies (e.g., gender or medications) as 
well as methodological aspects, moderated some of the ES estimates reported here (see Tables 
S9‒S11). Therefore, future studies should control the potential clinical and sociodemographic 
variables more precisely. It is important to mention that genetic ancestry was not considered in 
the studies included in this review, and the ethnic composition of the sample was frequently 
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missing, which did not allow specific subgroup analyses (see Table S8 which presents the 
methodological assessment). Futures studies should consider also genotyping ancestry-related 
SNPs together with the investigated genes to avoid spurious associations with the psychiatric or 
imaging phenotype. 
 Furthermore, an improvement in the transparency of protocols (e.g., through a priori 
publication of study procedures), as well as a better harmonization of neuroimaging procedures 
across centers are warranted. Large imaging genetics collaborative consortia, like ENIGMA, 
point that the inclusion of large samples with proper methodological harmonization across 
studies may improve the reproducibility of the field (Stein et al., 2012).  
 In this systematic review, very few candidate genes had been previously shown to have 
genome-wide significance for MDD (e.g., SLC6A15) (Choi et al., 2016; Hyde et al., 2016). 
Furthermore, the field still lacks replicated evidence for genes that are relevant to other 
pathways that may also be involved in MDD. For example, few imaging genetics studies have 
addressed the relevance of cytokine/chemokine (Kohler et al., 2017) as well as renin-
angiotensin (Vian et al., 2017) genes. Therefore, the recent identification of genome-wide 
significant risk variants associated with MDD open perspectives for imaging genetics studies. 
The testing of genetic variants supported by GWAS studies or by convergent sources of 
experimental and clinical evidence could enhance the robustness of findings in this field (Carter 
et al., 2017). Another innovative research avenue in imaging genetics studies is the assessment 
of polygenic risk scores on brain structure and function, although there are also concerns of the 
lack of genotype-phenotypic cross-trait convergence (Bogdan et al., 2017). Lastly, future 
efforts with a systematic collection of participant-level data may be able to formally test for 
interaction effects (for example, between group and genotypes) to provide incremental 
evidence to the stratified analysis herein conducted.  
4.3. Conclusion 
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This systematic review and meta-analysis indicates that imaging genetics studies in MDD have 
expanded at a rapid pace. However, few replicated findings involving the 5-HTTLPR and 
BDNF Val66Met polymorphism could be meta-analyzed. The 5-HTTLPR ‘S’ allele was 
associated with WM microstructural abnormalities mainly in the corpus callosum, while the 
BDNF Val66Met ‘Met’ allele was associated with a higher GM volume as well as 
hyperactivation or failure to deactivate the right MFG. Although promising, these findings 
require replication in well-designed studies with adequate statistical power. An improvement in 
transparency, as well as methodological refinements in imaging genetics studies, may provide 
more robust and replicable findings within the context of precision psychiatry (Vian et al., 
2017). Furthermore, the adoption of trans-diagnostic approaches [such as the US NIMH RDoC 
framework; Cuthbert and Insel (2013)] could provide novel biologically validated constructs to 
be tested in imaging genetics studies, and also increase the statistical power of studies, which 
this meta-analysis found to be low. 
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FIGURE LEGENDS: 
 
Fig. 1. PRISMA flowchart of study selection process. 
Fig. 2. Forest plots of studies that assessed differences in total hippocampal volumes in 
participants with MDD carrying genetic risk variants (RCs) versus non- carriers (NRCs) 
of (a) 5-HTTLPR and (b) BDNF Val66Met polymorphisms. For the 5-HTTLPR, RCs are 
carriers of the short ‘S’ allele, and for the BDNF Val66Met, RCs are carriers of the Met allele. 
Effect sizes (ESs) are synthesized as Hedges’s g (and 95% CIs) under random-effects 
modelling. Squares depict ES of individual studies (dimension is proportional to study weight), 
and diamonds represent summary ES estimates. A positive ES represent lower volumes in RCs 
relative to NRCs. * The Frodl, 2004 and Hickie, 2007 studies reported measures of the right 
and left hippocampi combined, while the other studies reported separate measures for the right 
or left sides. In these studies, the right and left values were first combined within the study to 
provide effect sizes. 
Fig. 3. Anatomical distribution of diffusion tensor imaging (DTI) fractional anisotropy 
(FA) changes in MDD subjects carrying the 5-HTTLPR short ‘S’ risk-allele vs. non-
carriers of the risk allele (long ‘L’ allele). Areas with reduced FA in the risk carriers include 
the corpus callosum, the left superior longitudinal fasciculus III and right cortico-spinal 
projections. The FA map is superimposed on a high-resolution T1-weighted template with 
skeletons for the brain tracts. Data are shown going from the right hemisphere to the left 
hemisphere. The skeletons represented in each small image are: 1, Right cortico-spinal 
projections; 2, Right thalamus; 3, Brain-stem; 4, Left cortico-spinal projections; 5-7, Left 
inferior fronto-occipital fasciculus/optic radiations; 8, Left superior longitudinal fasciculus. 
Abbreviations: MDD, Major depressive disorder; 5-HTTLPR, Serotonin transporter- linked 
promoter region. 
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Fig 4. Increases in gray matter with hyperactivation (or failure to deactivate) in the right 
middle frontal gyrus among MDD participants carrying the BDNF Val66Met ‘Met’ risk-
allele vs non-carriers (‘Val’ allele). Abbreviations: MDD, Major depressive disorder; BDNF, 
brain-derived neurotrophic factor. 
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Table 1. Primary meta-analyses of studies measuring region-of-interest volume or activation in 
carriers vs. non-carriers of 5-HTTLPR or BDNF Val66Met polymorphisms in participants with 
MDD or healthy controls. For the 5-HTTLPR, RCs are carriers of the short ‘S’ allele, and for the BDNF 
Val66Met, RCs are carriers of the ‘Met’ allele. 
Gene and 
region of 
interest 
N 
stu
die
s 
N
  
R
C 
N  
N
R
C 
ES 
(95% 
CI) 
P-
value 
(overal
l)* 
I
2 
P-
value 
(Egger
) † 
Small-
study 
effects ‡ 
Fail
-
safe 
N 
Adjusted 
ES (95% 
CI)§ 
MDD           
5-HTTLPR 
Total 
hippocampus 
volume 
8 
2
1
1 
9
9 
0.193 (-
0.074 ‒ 
0.460) 
0.157 
1
5
.
5 
0.321 N 0 
0.193 (-
0.074 ‒ 
0.460) 
5-HTTLPR 
Right 
hippocampus 
volume 
6 
1
5
7 
6
8 
0.318 (-
0.040 ‒ 
0.676) 
0.082 
2
7
.
9 
0.424 N 1 
0.318 (-
0.040 ‒ 
0.676) 
5-HTTLPR 
Left 
hippocampus 
volume 
6 
1
5
7 
6
8 
0.269 (-
0.095 ‒ 
0.633) 
0.147 
3
0
.
0 
0.447 N 0 
0.269 (-
0.095 ‒ 
0.633) 
BDNF Total 
hippocampus 
volume 
8 
1
4
2 
2
4
4 
0.029 (-
0.243 ‒ 
0.302) 
0.832 
3
5
.
6 
0.348 N 0 
0.029 (-
0.243 ‒ 
0.302) 
BDNF Right 
hippocampus 
volume 
8 
1
4
2 
2
4
4 
0.034 (-
0.293 ‒ 
0.361) 
0.837 
5
4
.
6 
0.505 N 0 
0.034 (-
0.293 ‒ 
0.361) 
BDNF Left 
hippocampus 
volume 
8 
1
4
2 
2
4
4 
0.027 (-
0.209 ‒ 
0.263) 
0.825 
1
7
.
2 
0.214 N 0 
0.027 (-
0.209 ‒ 
0.263) 
5-HTTLPR 
Total amygdala 
function 
3 
8
1 
3
3 
-0.896 (-
2.099 ‒ 
0.308) 
0.145 
8
4
.
8 
0.377 N 6 
-0.896 (-
2.099 ‒ 
0.308) 
Healthy 
Controls 
          
5-HTTLPR 
Total 
hippocampus 
volume 
5 
1
6
0 
7
0 
0.200 (-
0.081 ‒ 
0.482) 
0.163 0 0.035 Y 0 
0.127 (-
0.133 ‒ 
0.387) 
5-HTTLPR 
Right 
hippocampus 
volume 
4 
1
5
2 
6
2 
0.157 (-
0.137 ‒ 
0.452) 
0.296 
0
.
0 
0.079 Y 0 
0.080 (-
0.180 ‒ 
0.340) 
5-HTTLPR 
Left 
4 
1
5
6
2 
0.146 (-
0.149 ‒ 
0.332 
0
.
0.100 N 0 
0.064 (-
0.197 ‒ 
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hippocampus 
volume 
2 0.440) 0 0.324) 
BDNF Total 
hippocampus 
volume 
6 
1
3
6 
2
4
0 
0.221 (-
0.207 ‒ 
0.649) 
0.311 
7
3
.
4 
0.662 N 0 
0.221 (-
0.207 ‒ 
0.649) 
BDNF Right 
hippocampus 
volume 
6 
1
3
6 
2
4
0 
0.264 (-
0.269 ‒ 
0.796) 
0.331 
8
2
.
6 
0.609 N 1 
0.264 (-
0.269 ‒ 
0.796) 
BDNF Left 
hippocampus 
volume 
6 
1
3
6 
2
4
0 
0.177 (-
0.151 ‒ 
0.504) 
0.291 
5
5
.
6 
0.734 N 0 
0.177 (-
0.151 ‒ 
0.504) 
5-HTTLPR 
Total amygdala 
function 
3 
5
4 
2
3 
-0.364 (-
1.775 ‒ 
1.047) 
0.613 
8
6
.
5 
0.670 N 0 
-0.364 (-
1.775 ‒ 
1.047) 
Abbreviations: CI, confidence interval; ES, effect size; 5-HTTLPR, Serotonin transporter-linked promoter 
region; BDNF, brain-derived neurotrophic factor; MDD, major depressive disorder; RC, risk-allele carriers; 
NRC, non-risk carriers; Y, Yes; N, No; NA, not available due to the small number of studies; statistically 
significant results are in bold.  
* In Z-test of overall effect. 
† In Egger’s test of publication bias. 
‡ P < 0.1 in Egger’s test of publication bias and effect size of the largest study more conservative than the 
overall effect size or in the opposite direction. 
§ Adjusted using Duval and Tweedie’s trim-and-fill procedure. 
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Highlights 
 Genetic-neuroimaging paradigms may provide neurobiological insights to 
heterogeneous phenotypes like depression; 
 A systematic review and meta-analysis of gene- imaging studies involving samples with 
depression was performed; 
 Sixty-five studies (N=4034 participants with depression) met inclusion criteria; 
 Carriers of the BDNF Val66Met risk allele may have hyperactivation and elevated gray 
matter volumes of the right middle frontal gyrus; 
 Exploratory voxel-wise meta-analysis suggests that carriers of the 5-HTTLPR risk 
allele may have white matter microstructural abnormalities compared to non-carriers 
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Figure 1
Figure 2
Figure 3
Figure 4
